Amryt Pharma (Nasdaq:AMYT) - Aandelenkoers, Nieuws & Analyse

AMYT Overzicht aandelen

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases.

Over het bedrijf

AMYT fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

De winst zal naar verwachting met 53.88% per jaar groeien

De winst is de afgelopen 5 jaar met 34.4% per jaar gegroeid

Risicoanalyse

Geen risico's gedetecteerd voor AMYT uit onze risicocontroles.

Amryt Pharma plc Concurrenten

Evolus

NasdaqGM:EOLS

US$1.1b

ANI Pharmaceuticals

NasdaqGM:ANIP

US$1.1b

Collegium Pharmaceutical

NasdaqGS:COLL

US$1.1b

Liquidia

NasdaqCM:LQDA

US$926.5m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Amryt Pharma
Historische aandelenkoersen
Huidige aandelenkoers	US$14.70
52 Week Hoogtepunt	US$14.77
52 Week Laag	US$6.41
Bèta	0.75
11 maand verandering	0.96%
3 maanden verandering	-0.14%
1 Jaar Verandering	86.55%
33 jaar verandering	n/a
5 jaar verandering	n/a
Verandering sinds IPO	84.91%

Recent nieuws en updates

Recent updates

Amryt gets EMA panel nod for Mycapssa to retain orphan drug status in EU

Oct 18

Amryt growth hormone disorder drug Mycapssa gets EMA panel nod for EU approval

Sep 16

Amryt gets British marketing approval & orphan drug designation for rare skin disease gel

Sep 08

Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition

Jul 14

Amryt and Medison Pharma inks distribution deal for Juxtapid, Lojuxta and Myalept

Feb 04

Amryt's AP103 an Orphan Drug in U.S. for skin blistering disorder

Dec 23

Amryt Group's Lojuxta receives marketing approval in Brazil

Dec 09

Rendement voor aandeelhouders

	AMYT	US Pharmaceuticals	US Markt
7D	0.7%	-5.0%	-1.9%
1Y	86.5%	14.1%	30.4%

Rendement versus industrie: AMYT overtrof de US Pharmaceuticals industrie, die het afgelopen jaar een rendement 14.1 % opleverde.

Rendement versus markt: AMYT overtrof de US markt, die het afgelopen jaar een rendement opleverde van 30.4 %.

Prijsvolatiliteit

Is AMYT's price volatile compared to industry and market?
AMYT volatility
AMYT Average Weekly Movement	0.4%
Pharmaceuticals Industry Average Movement	9.4%
Market Average Movement	6.0%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: De aandelenkoers van AMYT is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van AMYT is het afgelopen jaar gedaald van 16% naar 0%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2015	289	Joe Wiley	www.amrytpharma.com

Amryt Pharma plc Samenvatting

Hoe verhouden de winst en inkomsten van Amryt Pharma zich tot de beurswaarde?
AMYT fundamentele statistieken
Marktkapitalisatie	US$940.67m
Inkomsten(TTM)	-US$790.00k
Inkomsten(TTM)	US$243.62m

3.9x

P/S-verhouding

-1,191x

Koers/Winstverhouding

Is AMYT overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
AMYT resultatenrekening (TTM)
Inkomsten	US$243.62m
Kosten van inkomsten	US$111.31m
Brutowinst	US$132.32m
Overige uitgaven	US$133.11m
Inkomsten	-US$790.00k

Laatst gerapporteerde inkomsten

Sep 30, 2022

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.012
Brutomarge	54.31%
Nettowinstmarge	-0.32%
Schuld/Eigen Vermogen Verhouding	64.3%

Hoe presteerde AMYT op de lange termijn?

Bekijk historische prestaties en vergelijking

AMYT Overzicht aandelen

Beloningen

Risicoanalyse

Amryt Pharma plc Concurrenten

NasdaqGM:EOLS

US$1.1b

NasdaqGM:ANIP

US$1.1b

NasdaqGS:COLL

US$1.1b

NasdaqCM:LQDA

US$926.5m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH

Amryt Announces European Commission Approves Mycapssa® for the Treatment of Acromegaly

Amryt Pharma plc Re-Affirms Revenue Guidance for the Year 2022

Amryt Pharma plc to Report Q3, 2022 Results on Nov 03, 2022

Amryt Announces COMP Adopts Positive Opinion on Orphan Disease Designation for Mycapssa for Treatment of Acromegaly

Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta (Metreleptin)

Recent updates

Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH

Amryt Announces European Commission Approves Mycapssa® for the Treatment of Acromegaly

Amryt Pharma plc Re-Affirms Revenue Guidance for the Year 2022

Amryt Pharma plc to Report Q3, 2022 Results on Nov 03, 2022

Amryt Announces COMP Adopts Positive Opinion on Orphan Disease Designation for Mycapssa for Treatment of Acromegaly

Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta (Metreleptin)

Amryt gets EMA panel nod for Mycapssa to retain orphan drug status in EU

Amryt growth hormone disorder drug Mycapssa gets EMA panel nod for EU approval

Amryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez(R) in Great Britain

Amryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez(R) in Great Britain

Amryt gets British marketing approval & orphan drug designation for rare skin disease gel

Amryt Pharma plc Provides Earnings Guidance for the Full Year 2022

Amryt Pharma plc to Report Q2, 2022 Results on Aug 04, 2022

Amryt Receives Orphan Drug Designation from the FDA for Mycapssa(R) (oral octreotide) for the Treatment of Carcinoid Syndrome

Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition

Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer

Amryt to Pursue Formal Dispute Resolution for Oleogel-S10 (Filsuvez®) NDA

Amryt Announces European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB

Amryt's Filsuvez gets approval in EU to treat rare skin disorder

Amryt Presents Data for Mycapssa (Oral Octreotide) from OPTIMAL and MPOWERED Phase 3 Trials at ENDO 2022

Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa(R) (oral octreotide) at ENDO 2022

Amryt Pharma plc, Annual General Meeting, Jun 30, 2022

Amryt Pharma plc Announces New Patent for Mycapssa®

Amryt Pharma plc Reaffirms Revenue Guidance for Fiscal Year 2022

CHMP Adopts positive opinion for Filsuvez(R) for the treatment of Dystrophic and Junctional EB

Amryt Pharma plc to Report Q1, 2022 Results on May 04, 2022

Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa® (oral octreotide) from the 2nd Year of OPTIMAL Open Label Extension Study in Acromegaly Patients

Amryt Announces Successful Bioavailability Study for Mycapssa® (Octreotide Capsules)

Amryt Receives Complete Response Letter from the U.S. Food and Drug Administration for Oleogel-S10 NDA

Amryt Announces Oleogel-S10 EMA Regulatory Update

Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide)

The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients

Amryt Pharma: Advancing Novel Treatments For Rare And Debilitating Conditions

Amryt Pharma plc Provides Update on Regulatory Review Process for Oleogel-S1

Amryt Announces the Cancellation of Admission of Its Ordinary Shares to Trading on AIM

Amryt Pharma plc Revises Revenue Guidance for the Year 2021

Amryt Pharma plc Announces Earnings Guidance for the Fiscal Year 2021

Amryt Pharma plc completed the acquisition of Chiasma, Inc. from MPM Capital and others.

U.S. Food and Drug Administration Confirms Amryt’s New Drug Application for Oleogel-S10 Will Not Require an Advisory Committee Meeting

U.S. Food and Drug Administration Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa

Amryt Pharma plc entered into an agreement to acquire Chiasma, Inc. from MPM Capital and others for approximately $290 million.

Chiasma surges on merger agreement with Amryt

Amryt and Medison Pharma Canada Sign Distribution Agreement for Myalepta (Metreleptin) in Canada

Amryt Pharma plc to Report Q4, 2020 Results on Mar 04, 2021

Amryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel

Amryt and Medison Pharma inks distribution deal for Juxtapid, Lojuxta and Myalept

Amryt Pharma plc Receives Reimbursement Approval from Nice for Myalepta in England and Wales

Amryt's AP103 an Orphan Drug in U.S. for skin blistering disorder

Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (Lomitapide) in Saudi Arabia

Amryt Group Receives Marketing Authorisation Approval for Lojuxta in Brazil

Amryt Group's Lojuxta receives marketing approval in Brazil

Amryt Pharma plc Raises Sales Guidance for the Full Year 2020

Amryt Announces Positive Results from Phase 3 Trial of Filsuvez® in Epidermolysis Bullosa

Amryt Signs Distribution Agreement with Swixx BioPharma AG

Amryt and Swixx Sign Distribution Deal for Lojuxta

Amryt Pharma plc to Report Q3, 2020 Results on Nov 05, 2020

Amryt Pharma Intends to Cancel the Admission of the Ordinary Shares to Trading on the Euronext Growth Market

Rendement voor aandeelhouders

Prijsvolatiliteit